Quince Therapeutics Sells AIDE Assets; President Steps Down

What Happened
Quince Therapeutics, Inc. announced on September 8, 2026 that it completed the sale of all issued and outstanding equity of its subsidiary Quince Therapeutics SpA, certain intellectual property related to its AIDE (Autologous Intracellular Drug Encapsulation) technology and the eDSP product candidate, and all related AIDE/eDSP machines and systems to Ayma Therapeutics, Inc. Ayma paid $450,000 in cash as consideration. On the same date, Quince’s President, Charles Ryan, departed the company and entered into a Separation Agreement.

Key Details

• Sale completed: September 8, 2026; buyer: Ayma Therapeutics, Inc.; consideration: $450,000 in cash.
• Assets sold: equity of Quince SpA, specified IP relating to AIDE/eDSP (e.g., encapsulated dexamethasone sodium phosphate), and AIDE/eDSP machines and systems.
• Executive departure: Charles Ryan’s separation date was September 8, 2026; he signed a Separation Agreement and General Release.
• Severance payment: Quince will pay Mr. Ryan a lump sum of $1,014,489.04 (18 months base salary + 150% of 2026 target bonus pro‑rated to Sept 8, 2026 + 18 months COBRA premium coverage), payable within 30 days after the Separation Agreement becomes effective (the 8th day after his execution), subject to non‑revocation of the release.

Why It Matters

• The company transferred ownership of its AIDE/eDSP program (IP, subsidiary equity and systems) to Ayma and received $450,000 cash — a disposition of assets/acquisition by Ayma that removes those assets from Quince’s balance sheet.
• Quince has a contractual severance obligation to its departing President of just over $1.01 million, payable subject to the release conditions in the Separation Agreement.
• For investors, the filing documents a reduction in Quince’s AIDE/eDSP assets and a near‑term cash outflow tied to executive separation; both are material items affecting the company’s asset base and cash position.